MedTrace Logo

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

NCT07192939 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2025-12-24

No results posted yet for this study

Summary

To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。

Conditions

  • IPF and PPF

Interventions

DRUG

HRS-9813 capsules

HRS-9813 capsule; High dose

DRUG

HRS-9813 capsules

HRS-9813 capsule; Low dose

DRUG

HRS-9813 capsule mimetic

HRS-9813 capsule mimetic

Sponsors & Collaborators

  • Guangdong Hengrui Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-29
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07192939 on ClinicalTrials.gov